{"analyses":[{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.12","estimateComment":"Tremelimumab represents the numerator and Placebo the denominator","groupDescription":"H0: No difference between tremelimumab and placebo H1: Difference between tremelimumab and placebo","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.4081","pValueComment":"P-value was estimated using the method of Klein et al. 2007 and Whitehead and Whitehead 1991, stratified by EORTC status and Line of therapy.","paramType":"Hazard Ratio (HR)","paramValue":"0.92","statisticalComment":"The stratification factors included EORTC status and line of therapy as recorded in IVRS/IWRS.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"307"}]}],"title":"Number of patients with Events (Death)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"58"}]}],"title":"Number patients censored <= 2 weeks before DCO"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"}]}],"title":"Number of patients censored > 2 weeks before DCO"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"382"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"282"}],"units":"Participants"}],"description":"Overall survival (OS) by treatment arm","groups":[{"description":"Placebo.","id":"OG000","title":"PLACEBO"},{"description":"TREMELIMUMAB 10 mg/kg","id":"OG001","title":"TREMELIMUMAB"}],"paramType":"NUMBER","populationDescription":"ITT population","reportingStatus":"POSTED","timeFrame":"3 years.","title":"Overall Survival (OS)","type":"PRIMARY","typeUnitsAnalyzed":"Participants","unitOfMeasure":"Number of Participants"}